0.0011  0 (0%)		07-26 16:00
Open: 0.04 High: 0.04 Volume: 5,000		Pre. Close: Low: 0.0011 Market Cap: 0(M)

Short term
Mid term
Targets	6-month :	0.32	1-year :	0.52
Resists	First :	0.27	Second :	0.44
Pivot price	0.09
Supports	First :	0	Second :	0
MAs	MA(5) :	0.03	MA(20) :	0.1
	MA(100) :	0.52	MA(250) :	1.92
MACD	MACD :	-0.1	Signal :	-0.1
%K %D	K(14,3) :	0.8	D(3) :	1
RSI	RSI(14): 38.8
52-week	High :	8.29	Low :	0

Price has closed below its short-term moving average. Short-term moving average is currently below mid-term; and below long-term moving average. From the relationship between price and moving averages: This stock is BEARISH in short-term; and BEARISH in mid-long term.
[ AMPE ] has closed above bottom band by 25.5%. Bollinger Bands are 22.3% narrower than normal. The current width of the bands does not suggest anything about the future direction or movement of prices.

If tomorrow:	Open lower	Open higher
High:	0.04 - 0.04	0.04 - 0.04
Low:	0 - 0	0 - 0
Close:	0 - 0	0 - 0

Ampio Pharmaceuticals, Inc., a biopharmaceutical company, focuses on the development of immunomodulatory therapies for the treatment of pain from osteoarthritis in the United States. Its product pipeline includes AP-013, an intra-articular injection, which is in phase III clinical trial for the treatment of osteoarthritis of the knee; AP-017, an intravenous ampion treatment that is in Phase II clinical trial to treat adult COVID-19 patients requiring oxygen supplementation; AP-019, an Inhaled Ampion treatment, which is in Phase II clinical trial for the treatment of Adults with Respiratory Distress Due to COVID-19; and AP-018 that is in Phase I clinical trial to treat patients with prolonged respiratory symptoms due to COVID-19. The company is headquartered in Englewood, Colorado.

Fri, 26 Jul 2024
Ampio Pharmaceuticals (NYSE:AMPE) Research Coverage Started at StockNews.com - Defense World

Wed, 03 Apr 2024
Ampio Pharmaceuticals Received Audit Opinion with Going Concern Explanation - PR Newswire

Mon, 25 Mar 2024
Ampio Pharmaceuticals announces voluntary delisting and SEC deregistration (NYSE:AMPE) - Seeking Alpha

Mon, 25 Mar 2024
Ampio Announces Voluntary Delisting and SEC Deregistration - PR Newswire

Wed, 14 Feb 2024
Ampio Provides Update on Results from Pre-IND Enabling Studies - PR Newswire

Fri, 01 Dec 2023
Ampio Pharma (NYSE: AMPE) up 194% y’day - and down 27% after hours - Dhaka Tribune

Price to Book Value: P/BV, a ratio used to compare book value to its current market price, to gauge whether a stock is valued properly.	Underperform
Price to Earnings: PE, the ratio for valuing a company that measures its current share price relative to its earnings per share (EPS).	Neutral
Discounted cash flow: DCF, a valuation method used to estimate the value of an investment based on its expected future cash flows.	Outperform
Return on Assets: ROA, indicates how profitable a company is in relation to its total assets, how efficiently uses assets to generate a profit.	Underperform
Return on Equity: ROE, a measure of financial performance calculated by dividing net income by equity. a gauge of profitability and efficiency.	Underperform
Debt to Equity: evaluate financial leverage, reflects the ability of equity to cover outstanding debts in the event of a business downturn.	Neutral

Exchange: AMEX
Sector: Healthcare
Industry: Biotechnology
Shares Out	1 (M)
Shares Float	1 (M)
Held by Insiders	2.1 (%)
Held by Institutions	0.3 (%)
Shares Short	35 (K)
Shares Short P.Month	41 (K)

EPS	-11.7
EPS Est Next Qtrly	0
EPS Est This Year	0
EPS Est Next Year	0
Book Value (p.s.)	6.67
Profit Margin	0 %
Operating Margin	0 %
Return on Assets (ttm)	-47.3 %
Return on Equity (ttm)	-91.6 %
Qtrly Rev. Growth	0 %
Gross Profit (p.s.)	0
Sales Per Share	0
EBITDA (p.s.)	-11.65
Qtrly Earnings Growth	0 %
Operating Cash Flow	-11 (M)
Levered Free Cash Flow	-7 (M)

PE Ratio	-0.01
PEG Ratio	0
Price to Book value	0
Price to Sales	0
Price to Cash Flow	-0.01

Dividend	0
Forward Dividend	0
Dividend Yield	0%
Dividend Pay Date	Invalid DateTime.
Ex-Dividend Date	Invalid DateTime.